Charles River Laboratories (CRL) stock soared 5.24% in Monday's intraday trading session. The rise appears to be driven by positive research updates from analysts covering the company.
According to TD Cowen, the firm cut its price target on CRL to $179 from $182 but maintained a Hold rating on the stock. The adjustment followed Charles River's recent financial results and likely factors in the analysts' updated outlook for the company.
Additionally, broader market sentiment towards Charles River Laboratories seems favorable, as evidenced by the news roundup highlighting various analysts raising their ratings and price targets on the stock. The positive analyst views suggest optimism around CRL's growth prospects and potential earnings performance.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。